德国医学专家22日公布的一项研究结果表明，在治疗癌症患者时使用热疗和化疗相结合的方法比单一接受化疗效果更好，无瘤期更长。
实验室研究发现，在针对肌肉、脂肪、关节组织等软组织实施热疗和化疗时，热疗促使癌细胞反应的比例是化疗的两倍。更为重要的是，在结合热疗和化疗过程中，热疗不会增加化疗的副作用。
尽管仍需进一步证实，但专家说，热疗可辅助化疗或有助于减少化疗剂量。
热疗法源于一种“区域高热”技术。治疗时，可使电磁能量集中在患者肿瘤周围组织，使温度升至40摄氏度至43摄氏度。进行此项研究的德国慕尼黑大学肿瘤学教授罗尔夫·伊塞尔斯说，热量不仅能杀死癌细胞，似乎还能通过增强癌细胞的敏感性使化疗取得更佳效果。
伊塞尔斯说，接受热疗与化疗相结合的软组织恶性肿瘤患者，“各项疗效指标良好”，“与单纯接受化疗相比，接受混合疗法近3年后，患者癌症在同一部位复发的几率降低42％，患者死亡率也下降”。
两组临床患者试验中，单纯接受化疗患者的平均无瘤期为18个月，而接受热疗与化疗相结合患者的平均无瘤期为32个月，增加30％。
伊塞尔斯说：“热疗与放射疗法结合治疗乳腺癌和宫颈癌的疗效已经显现。用热疗辅助化疗治疗包括胰腺癌和直肠癌在内的研究眼下已经起步。我们期待此项研究结果能被临床应用于治疗其他局部癌症晚期患者。”（生物谷Bioon.com）
生物谷推荐原始出处：
International Journal of Hyperthermia 2009, Vol. 25, No. 4, Pages 262-272
Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells
Valeria Milani, MD1,2, Monika Lorenz2, Valeria Milani, MD1,2, Monika Lorenz2, Marc Weinkauf3, Malte Rieken3, Alessandro Pastore1,3, Martin Dreyling1,3 and Rolf Issels1,2
1Department of Medical Oncology, University Medical Center Grosshadern, Munich, Germany
2CCG Hyperthermia, Helmholtz Zentrum München - H?matologikum, Munich, Germany
3AG Dreyling, Helmholtz Zentrum München - H?matologikum, Munich, Germany
The proteasome inhibitor bortezomib exhibits antitumor activity in many malignancies including mantle cell lymphoma (MCL). Unfortunately, many patients fail to respond to treatment or become refractory. Hyperthermia is an effective chemosensitizer that in combination with some chemotherapeutic agents has shown clinical activity in phase II and III studies. The aim of this study was to use MCL cell lines to investigate the potential benefit of combining clinically relevant doses of bortezomib with two different thermal doses (41.8°C/120 min and 44°C/30 min) that mimic the heterogeneity of the temperature distributions achieved within tumors during hyperthermia. Treated tumor cells were assessed for proliferation using the WST-1 assay and for apoptosis by annexin V staining, while heat shock protein (HSP) levels were determined following western blot analysis. Our results demonstrated that MCL cell lines that are sensitive to bortezomib are also thermosensitive and have low basal expression of hsp27, whereas the bortezomib-resistant MCL cell line strongly expresses hsp27 and is thermoresistant. Interestingly, pre-treatment of MCL cell lines with heat at the two different thermal doses, and the transient elevation of hsp27 and hsp70, do not impair their primary sensitivity to bortezomib. Finally, we show that the concurrent treatment of heat and bortezomib results in additive killing in MCL cell lines.In conclusion, these results suggest that the application of bortezomib, under thermal conditions, in mantle cell lymphoma cells may be beneficial and warrants further investigation.
